Study summary
Capivasertib added 7.5 months before progression in PTEN-deficient disease
33.2months without progression, vs 25.7 with placebo
What was tested
Capivasertib, an AKT-blocking pill, or placebo added to abiraterone and ADT for metastatic hormone-sensitive prostate cancer that has lost the PTEN protein (about 1 in 4 tumors).
What they found
- Median radiographic progression-free survival was 33.2 vs 25.7 months.
- Survival was not yet different (immature data).
- Diarrhea (51.9%), high blood sugar (38.0%) and rash (35.4%) were common.
What it means
First evidence that a PTEN tumor test could guide treatment.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.